Coretext

Coretexthttp://coretext.orgthe Reckitt-Benckiser buprenorphine bibliography<![CDATA[( BUPP09035 - 14 July 2008) Long-term opioid management for chronic noncancer pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09035<![CDATA[( BUPP09034 - 14 July 2008) Test strip handling in screening for drugs of abuse in the clinical toxicological setting.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09034<![CDATA[( BUPP09033 - 14 July 2008) Enhancing capacities: Right or wrong?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09033<![CDATA[( BUPP09032 - 14 July 2008) Harm reduction and equity of access to care for French prisoners: A review.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09032<![CDATA[( BUPP09031 - 14 July 2008) Temporary services for patients in need of chronic care.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09031<![CDATA[( BUPP09030 - 14 July 2008) Diagnostics and therapy of chronic pancreatitis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09030<![CDATA[( BUPP09029 - 14 July 2008) Variable response to opioid treatment: Any genetic predictors within sight?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09029G of the mu- opioid receptor, the accumulated evidence is sufficient to suggest a clinically relevant effect for an opioid used for moderate or severe pain. Still the data are valid only at the group level and cannot be used to predict treatment outcome in individual patients. Only a few of the symptoms often seen as opioid adverse effects in palliative care, such as nausea, vomiting, constipation and sedation, have been associated with genetic variants in various genes, but the results have been based on case reports, healthy volunteers or post-operative patients. So far, there is no clear evidence that genetic markers can be used to predict opioid efficacy or adverse effects in palliative care patients. This reflects the general lack of studies performed in the context of palliative care, the lack of sufficiently scaled studies and the lack of international standards for the assessment of subjective symptoms. ]]><![CDATA[( BUPP09028 - 14 July 2008) Receptor functions.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09028<![CDATA[( BUPP09027 - 14 July 2008) Thoracic epidural catheterization leading to delayed transient neurological symptoms with normal imaging findings.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09027<![CDATA[( BUPP09026 - 14 July 2008) Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09026<![CDATA[( BUPP09025 - 14 July 2008) Suicidality in opioid-dependent subjects.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09025<![CDATA[( BUPP09024 - 14 July 2008) Oral substitution treatments for opioid dependence (Comments)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09024<![CDATA[( BUPP09046 - 21 July 2008) Local infiltration analgesia: A technique for the control of acute postoperative pain following knee and hip surgery - A case study of 325 patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09046<![CDATA[( BUPP09045 - 21 July 2008) Gender issues and the pharmacotherapy of substance abuse.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09045<![CDATA[( BUPP09044 - 21 July 2008) Prescription of opiates in medical practice.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09044<![CDATA[( BUPP09043 - 21 July 2008) Attitudes and knowledge of substance misusers regarding buprenorphine and methadone maintenance therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09043<![CDATA[( BUPP09042 - 21 July 2008) Opioids and the control of respiration.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09042<![CDATA[( BUPP09041 - 21 July 2008) Simultaneous screening of buprenorphine, ketamine, LSD, MDMA, methaqualone, fentanyl, oxycodone, hydromorphone, propoxyphene and the dilution marker creatinine in urine using Evidence biochip array technology.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09041<![CDATA[( BUPP09040 - 21 July 2008) The buprenorphine Assay* on the Olympus (R) analyzers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09040<![CDATA[( BUPP09039 - 21 July 2008) Comparison of two Buprenorphine immunoassays and their ability to determine Buprenorphine prevalence, compliance, diversion and abuse.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09039<![CDATA[( BUPP09038 - 21 July 2008) Buprenophine enzyme immunoassay on Synchron systems.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09038<![CDATA[( BUPP09037 - 21 July 2008) Method for reducing pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09037<![CDATA[( BUPP09036 - 21 July 2008) Driving ability under opioids: current assessment of published studies.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09036<![CDATA[( BUPP09059 - 28 July 2008) Case series of buprenorphine injectors in Kuala Lumpur, Malaysia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09059<![CDATA[( BUPP09058 - 28 July 2008) Pharmacogenetic treatments for drug addiction: Alcohol and opiates.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09058<![CDATA[( BUPP09057 - 28 July 2008) Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09057<![CDATA[( BUPP09056 - 28 July 2008) Call for feedback on managing chronic pain and opioid addiction.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09056<![CDATA[( BUPP09055 - 28 July 2008) Prescription opioid abuse and dependence among physicians: Hypotheses and treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09055<![CDATA[( BUPP09054 - 28 July 2008) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. in vitro-in vivo correlation with ketoconazole.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09054<![CDATA[( BUPP09053 - 28 July 2008) An emerging trend of buprenorphine abuse resulting in severe neurologic deficits.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09053<![CDATA[( BUPP09052 - 28 July 2008) Combined spinal-epidural anesthesia for renal transplantation.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09052<![CDATA[( BUPP09051 - 28 July 2008) A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09051<![CDATA[( BUPP09050 - 28 July 2008) Stepping into the wide world.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09050<![CDATA[( BUPP09049 - 28 July 2008) Community treatment programs take up buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09049<![CDATA[( BUPP09048 - 28 July 2008) Response: integrating buprenorphine therapy into clinical practice.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09048<![CDATA[( BUPP09047 - 24 July 2008) A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine / naloxone combination (suboxone)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09047 22 mg) of buprenorphine to the combination product, dose adjustments may be necessary especially in the later phase of the treatment. We recommend that a transfer from Subutex to Suboxone should be carefully discussed and planned in advance with the patients and after the transfer adverse events should be regularly monitored. With regard of buprenorphine IV abuse, the combination product seems to have a less abuse potential than buprenorphine alone. ]]><![CDATA[( BUPP09082 - 11 August 2008) Endogenous Candida endophthalmitis in drug misusers injecting intravenous buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09082<![CDATA[( BUPP09081 - 11 August 2008) Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09081<![CDATA[( BUPP09080 - 11 August 2008) Therapy goals, evaluation and health-economic aspects of the therapy of drug-dependent.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09080<![CDATA[( BUPP09079 - 11 August 2008) Transdermal drug delivery systems.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09079<![CDATA[( BUPP09078 - 11 August 2008) Addressing Canine and Feline Aggression in the Veterinary Clinic.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09078<![CDATA[( BUPP09077 - 11 August 2008) Neuropathic pain - The view of combined therapy with the use of opioids.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09077<![CDATA[( BUPP09076 - 11 August 2008) Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09076<![CDATA[( BUPP09075 - 11 August 2008) On drug treatment and social control: Russian narcology's great leap backwards.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09075<![CDATA[( BUPP09074 - 11 August 2008) Controversies in translational research: Drug self-administration]]>http://coretext.org/bupp_detail.asp?recno=BUPP09074<![CDATA[( BUPP09073 - 11 August 2008) Mucositis postradiotherapy]]>http://coretext.org/bupp_detail.asp?recno=BUPP09073<![CDATA[( BUPP09072 - 11 August 2008) Comparison of anesthetic induction in cats by use of isoflurane in an anesthetic chamber with a conventional vapor or liquid injection technique.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09072<![CDATA[( BUPP09083 - 15 August 2008) Sublingual Buprenorphine for Treatment of Neonatal Adstinence Syndrome: A Randomized Trial]]>http://coretext.org/bupp_detail.asp?recno=BUPP09083<![CDATA[( BUPP09084 - 15 August 2008) Treating Pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09084<![CDATA[( BUPP09085 - 18 August 2008) The neurobiology of opioid dependence: implications for treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09085<![CDATA[( BUPP09086 - 18 August 2008) Comparison of characteristics of opioid-using pregnant women in rural and urban settings.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09086<![CDATA[( BUPP09087 - 18 August 2008) State policy influence on the early diffusion of buprenorphine in community treatment programs.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09087<![CDATA[( BUPP09088 - 18 August 2008) Addiction: a chronic medical condition.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09088<![CDATA[( BUPP09089 - 18 August 2008) Buprenorphine use by the smoking route in gaols in NSW.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09089<![CDATA[( BUPP09090 - 18 August 2008) Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09090<![CDATA[( BUPP09091 - 18 August 2008) The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: Guidance for clinical practice.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09091<![CDATA[( BUPP09092 - 18 August 2008) Transdermal buprenorphine (Transtec®) for the treatment of severe chronic pain]]>http://coretext.org/bupp_detail.asp?recno=BUPP09092<![CDATA[( BUPP09093 - 18 August 2008) Epidemiology of opioid pharmacy claims in the United States]]>http://coretext.org/bupp_detail.asp?recno=BUPP09093<![CDATA[( BUPP09094 - 18 August 2008) Opioid-induced hyperalgesia: Pathophysiology and clinical implications.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09094<![CDATA[( BUPP09095 - 18 August 2008) A patient-based national survey on postoperative pain management in France reveals significant achievements and persistent challenges.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09095<![CDATA[( BUPP09096 - 18 August 2008) Normative data of multifrequency tympanometry in rabbits.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09096<![CDATA[( BUPP09097 - 18 August 2008) Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09097<![CDATA[( BUPP09098 - 18 August 2008) Palliative medicine: Pain management according to time and step-by-step plan.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09098<![CDATA[( BUPP09099 - 18 August 2008) A clinical snapshot of transdermal buprenorphine in pain management.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09099<![CDATA[( BUPP09100 - 18 August 2008) Basic pharmacology of buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09100<![CDATA[( BUPP09101 - 18 August 2008) Cancer pain management modalities and positioning of oxycodone.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09101<![CDATA[( BUPP09102 - 18 August 2008) Predicting pain and pain responses to opioids.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09102<![CDATA[( BUPP09103 - 18 August 2008) The 3rd Asia Pacific Symposium on Pain Control, Singapore, September 1-3, 2006: Introduction and Overview]]>http://coretext.org/bupp_detail.asp?recno=BUPP09103<![CDATA[( BUPP09104 - 18 August 2008) Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): From Gilbert's syndrome to genetic organization and variability.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09104<![CDATA[( BUPP09105 - 18 August 2008) Pharmacogenetics of Gilbert's syndrome.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09105<![CDATA[( BUPP09106 - 18 August 2008) Monitored anaesthesia care in the elderly - Guidelines and recommendations.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09106<![CDATA[( BUPP09107 - 18 August 2008) Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09107<![CDATA[( BUPP09108 - 18 August 2008) Is hepatitis C prevalence decreasing among opiate-substituted drug users attending an addiction outpatient unit in France?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09108<![CDATA[( BUPP09109 - 18 August 2008) Relapse rate and outcome after liver transplantation (LT) in former intravenous drug (IVD) abusers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09109<![CDATA[( BUPP09110 - 26 August 2008) Management of cancer pain: ESMO Clinical Recommendations.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09110<![CDATA[( BUPP09111 - 26 August 2008) Formation of the N-methylpyridinium derivative to improve the detection of buprenorphine by liquid chromatography-mass spectrometry.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09111<![CDATA[( BUPP09112 - 26 August 2008) Methadone and buprenorphine treatment during pregnancy: what are the effects on infants?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09112<![CDATA[( BUPP09113 - 26 August 2008) Drug-induced dementia: A case/non-case study in the French pharmacovigilance database.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09113<![CDATA[( BUPP09114 - 26 August 2008) Pharmacokinetic approaches to treatment of drug addiction.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09114<![CDATA[( BUPP09115 - 26 August 2008) First, Remove the Offending Agent]]>http://coretext.org/bupp_detail.asp?recno=BUPP09115<![CDATA[( BUPP09116 - 26 August 2008) Efficacy and clinical management of buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09116<![CDATA[( BUPP09117 - 26 August 2008) Interactions between antiretroviral therapy (ART) and substitution medications in HIV-infected drug users.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09117<![CDATA[( BUPP09118 - 26 August 2008) Immunotherapies for drug addictions.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09118<![CDATA[( BUPP09119 - 26 August 2008) Hysteresis in drug response.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09119<![CDATA[( BUPP09120 - 26 August 2008) Addiction and substance misuse.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09120<![CDATA[( BUPP09121 - 26 August 2008) Characteristics of alcohol-dependent male inmates]]>http://coretext.org/bupp_detail.asp?recno=BUPP09121<![CDATA[( BUPP09122 - 26 August 2008) The nociceptin/orphanin FQ receptor: A target with broad therapeutic potential.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09122<![CDATA[( BUPP09123 - 01 September 2008) ADR news: Buprenorphine abuse. Cerebral embolism (first report) following parenteral administration: case report. Serious.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09123<![CDATA[( BUPP09124 - 01 September 2008) A comparative study of the ventilatory effects of four opioids administered at toxic doses in the rat.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09124<![CDATA[( BUPP09125 - 01 September 2008) Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09125<![CDATA[( BUPP09126 - 01 September 2008) Monitoring of the misuse of prescription drugs by clients of outpatient addiction treatment centres (PHAR-MON, formerly: ebis-med) - Monitoring of medication misuse.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09126<![CDATA[( BUPP09127 - 01 September 2008) Health care utilization and morbidity associated with methadone and buprenorphine treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09127<![CDATA[( BUPP09128 - 01 September 2008) Effects of epidurally administered morphine or buprenorphine on the thermal threshold in cats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09128<![CDATA[( BUPP09129 - 01 September 2008) Addiction and addiction medicine: Exploring opportunities for the general practitioner.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09129<![CDATA[( BUPP09130 - 01 September 2008) Pain in the elderley]]>http://coretext.org/bupp_detail.asp?recno=BUPP09130<![CDATA[( BUPP09131 - 01 September 2008) Intravenous regional anesthesia - First century (1908-2008). Beggining, development, and current status.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09131<![CDATA[( BUPP09132 - 01 September 2008) Early behavioral and histological outcomes following a novel traumatic partial nerve lesion.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09132<![CDATA[( BUPP09133 - 01 September 2008) Buprenorphine treatment in an urban community health center: What to expect.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09133<![CDATA[( BUPP09134 - 01 September 2008) Preliminary study of buprenorphine and bupropion for opioid-dependent smokers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09134<![CDATA[( BUPP09135 - 01 September 2008) Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV / AIDS]]>http://coretext.org/bupp_detail.asp?recno=BUPP09135<![CDATA[( BUPP09136 - 09 September 2008) ADR news: Buprenorphine. Somnolence and visual hallucinations following transdermal administration in an elderly patient: case report.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09136<![CDATA[( BUPP09137 - 09 September 2008) Pharmacogenetics of analgesics: toward the individualization of prescription.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09137<![CDATA[( BUPP09138 - 09 September 2008) Recommendations for treatment of neuropathic pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09138<![CDATA[( BUPP09139 - 09 September 2008) The management of neuropathic pain in cancer.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09139<![CDATA[( BUPP09140 - 09 September 2008) Effects of indomethacin and buprenorphine analgesia on the postoperative recovery of mice.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09140<![CDATA[( BUPP09141 - 09 September 2008) Harm reduction and control of HIV in IDUs in France.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09141<![CDATA[( BUPP09142 - 09 September 2008) Pain therapy in children and adolescents.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09142<![CDATA[( BUPP09143 - 09 September 2008) Oxycodone: A pharmacological and clinical review.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09143<![CDATA[( BUPP09144 - 09 September 2008) QTc interval prolongation and opioid addiction therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09144<![CDATA[( BUPP09145 - 09 September 2008) (Commentary) maintenance treatments across countries.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09145<![CDATA[( BUPP09146 - 09 September 2008) Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09146<![CDATA[( BUPP09147 - 09 September 2008) First meeting of the French CEIP (centres d'evaluation et d'information sur la pharmacodependance). Assessment of the abuse and pharmacodependence potential during drug development.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09147<![CDATA[( BUPP09148 - 09 September 2008) Efficacy and Safety of Transdermal Buprenorphine: A Randomized, Placebo-Controlled Trial in 289 Patients with Severe Cancer Pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09148<![CDATA[( BUPP09149 - 09 September 2008) (Commentary) modern treatment for prisoners.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09149<![CDATA[( BUPP09150 - 09 September 2008) Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone]]>http://coretext.org/bupp_detail.asp?recno=BUPP09150<![CDATA[( BUPP09151 - 09 September 2008) Opioid switching from transdermal buprenorphine to oxicodone in delirium: A case report.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09151<![CDATA[( BUPP09152 - 09 September 2008) Health Care Use in Patients With Chronic Intestinal Dysmotility Before and After Introducing a Specialized Day-Care Unit.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09152<![CDATA[( BUPP09153 - 09 September 2008) The postoperative analgesia procedures in children.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09153<![CDATA[( BUPP09154 - 16 September 2008) ADR news: Buprenorphine/naloxone abuse. First report of serotonin syndrome: case report. Serious.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09154<![CDATA[( BUPP09155 - 16 September 2008) Implementation of chronic care management for alcohol and drug dependence: Prescription of addiction and psychiatric medications.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09155<![CDATA[( BUPP09156 - 16 September 2008) Charateristics of individals utilizing 12 step programs while participating in buprenorphine-naloxone outpatient treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09156<![CDATA[( BUPP09157 - 16 September 2008) Buprenorphine-induced respiratory depression reversed by naloxone in a 2-year-old.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09157<![CDATA[( BUPP09158 - 16 September 2008) Drug treatment of opiate dependence in primary care - An update.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09158<![CDATA[( BUPP09159 - 16 September 2008) Evidence of the efficacy of major and minor opioids in the treatment of osteoarticular pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09159 6 weeks) musculoskeletal pain, of all ages and sexes, and under treatment with major or minor opioids irrespective of the duration of the treatment or route of administration. Control: placebo or any other analgesic, and 3) search criteria: reduction of pain (through the use of qualitative or continuous measures) and improvement of the quality of life. Major opiates resulted in a significantly greater percentage improvement of the pain compared to placebo in patients with chronic pain, with an acceptable evidence level. Major opiates by oral route also resulted in improvement of the WOMAC pain index compared to placebo in patients with osteoarthritis, with an acceptable evidence level. Major opiates by intraarticular route showed a significant improvement in the severity of pain compared to placebo in patients with peripheral osteoarthritis or rheumatoid arthritis, with a good evidence level. Major opiates by intravenous route in general resulted in a higher percentage response compared to placebo in patients with fibromyalgia and radiculopathy, with a slight evidence level. Major opiates by transdermal route resulted in a significantly higher percentage of patients with at least good improvement of the pain, a higher percentage response, and a greater number of patients with more than 6 h of uninterrupted sleep compared to placebo in patients with chronic pain secondary to cancer, musculoskeletal diseases or other situations that cause chronic pain, with a good evidence level. The evidence level is insufficient in regard to major opiates significantly improving pain when compared to anti-inflammatory drugs in patients with chronic lumbago or peripheral osteoarthritis. Tramadol is an efficient treatment for acute and chronic musculoskeletal pain. 23rd Sept 08 - message from the British Library - This paper is placed on a waiting list. ]]><![CDATA[( BUPP09160 - 16 September 2008) Pharmacology of opioids.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09160<![CDATA[( BUPP09161 - 16 September 2008) Rapamycin, mycophenolate mofetil, methylprednisolone, and cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-based conditioning regimen to induce partial tolerance to hind limb allografts without cytoreductive conditioning.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09161200 days) donor (BN)-specific (RT11, n = 6) hind limbs, yet rapidly rejected (20 +/- 2 days) third-party hind limbs (Wistar Furth (WF)). Lymphocytes of graft-tolerant animals demonstrated hyporesponsiveness in mixed lymphocyte cultures in a donor-specific manner. Tolerant graft histology showed no signs of acute and chronic rejection. CONCLUSIONS: The immunosuppressant and CTLA4-Ig-based conditioning regimen with donor BMT produced mixed chimerism and induced partial donor-specific tolerance to hind limb allografts. ]]><![CDATA[( BUPP09162 - 16 September 2008) (Drug therapy of opioid withdrawal).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09162<![CDATA[( BUPP09163 - 22 September 2008) Epidural analgesia during brachytherapy for cervical cancer patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09163<![CDATA[( BUPP09164 - 22 September 2008) Fentanyl transdermal matrix patch (Durotep® MT patch; Durogesic® DTrans®; Durogesic® SMAT): In adults with cancer-related pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09164<![CDATA[( BUPP09165 - 22 September 2008) Current recommondations on the evaluation of the impact of opioids on driving ability.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09165<![CDATA[( BUPP09166 - 22 September 2008) Candidate gene polymorphisms predicting individual sensitivity to opioids]]>http://coretext.org/bupp_detail.asp?recno=BUPP09166<![CDATA[( BUPP09167 - 22 September 2008) Opioid addiction and pregnancy: Perinatal exposure to buprenorphine affects myelination in the developing brain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09167<![CDATA[( BUPP09168 - 22 September 2008) Dividing transdermal plaster is not tolerable.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09168<![CDATA[( BUPP09169 - 22 September 2008) Oral versus transdermal treatment of cancer pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09169<![CDATA[( BUPP09170 - 22 September 2008) Late morbidity after duodenum-preserving pancreatic head resection with bile duct reinsertion into the resection cavity.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09170<![CDATA[( BUPP09171 - 22 September 2008) Treatment of chronic osteoarthritis pain: Effectivity and safety of a 7 day matrix patch with a lowdose buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09171<![CDATA[( BUPP09172 - 22 September 2008) Placebo Response: Relevance to the Rheumatic Diseases.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09172<![CDATA[( BUPP09173 - 22 September 2008) The Pharmacotherapy of Chronic Pain]]>http://coretext.org/bupp_detail.asp?recno=BUPP09173<![CDATA[( BUPP09174 - 22 September 2008) Regional haemodynamic responses to adenosine receptor activation vary across time following lipopolysaccharide treatment in conscious rats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09174<![CDATA[( BUPP09175 - 22 September 2008) Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09175<![CDATA[( BUPP09176 - 23 September 2008) Further investigation of the N-demethylation of tertiary amine alkaloids using the non-classical Polonovski reaction.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09176<![CDATA[( BUPP09177 - 29 September 2008) Serotonin syndrome triggered by a single dose of suboxone.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09177<![CDATA[( BUPP09178 - 29 September 2008) Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09178.05), indicating dose proportionality. The results of this study suggest that OTM buprenorphine may be an alternative for pain management in dogs. ]]><![CDATA[( BUPP09179 - 29 September 2008) How do you treat fibromyalgia in your practice?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09179<![CDATA[( BUPP09180 - 29 September 2008) 'Topping up' methadone: An analysis of patterns of heroin use among a treatment sample of Scottish drug users.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09180<![CDATA[( BUPP09181 - 29 September 2008) Urinary buprenorphine concentrations in patients treated with Suboxone® as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09181<![CDATA[( BUPP09182 - 29 September 2008) Chronic pain and opioidis dependence syndrome.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09182<![CDATA[( BUPP09183 - 29 September 2008) Studies on the analgesic and anti-inflammatory properties of crude extracts of sting ray, Dasyatis zugei (Muller and Henle 1841).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09183<![CDATA[( BUPP09184 - 29 September 2008) Pain and U-shaped dose responses: Occurrence, mechanisms, and clinical implications.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09184<![CDATA[( BUPP09185 - 29 September 2008) Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09185<![CDATA[( BUPP09186 - 29 September 2008) Murine renal ischaemia-reperfusion injury.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09186<![CDATA[( BUPP09187 - 29 September 2008) Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09187<![CDATA[( BUPP09188 - 29 September 2008) Effectiveness of non-steroidal anti-inflammatory drugs and epidural anaesthesia in reducing the pain and stress responses to a surgical husbandry procedure (mulesing) in sheep.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09188<![CDATA[( BUPP09189 - 06 October 2008) High cervical epidural neurostimulation for cluster headache: Case report and review of the literature.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09189<![CDATA[( BUPP09190 - 06 October 2008) The optimal temperature of first aid treatment for partial thickness burn injuries.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09190<![CDATA[( BUPP09191 - 06 October 2008) Overdose training and take-home naloxone for opiate users: Prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09191<![CDATA[( BUPP09192 - 06 October 2008) Motor cortex rTMS in chronic neuropathic pain: Pain relief is associated with thermal sensory perception improvement.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09192<![CDATA[( BUPP09193 - 06 October 2008) Coming to terms with complexity: a call to action for HIV prevention.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09193<![CDATA[( BUPP09194 - 06 October 2008) Drug withdrawal in newborns - Clinical data of 49 infants with intrauterine drug exposure: What should be done?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09194<![CDATA[( BUPP09195 - 06 October 2008) Pain therapy Part III. Opioid analgetic drugs.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09195<![CDATA[( BUPP09196 - 06 October 2008) Attitudes toward buprenorphine and methadone among opioid-dependent individuals.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09196<![CDATA[( BUPP09197 - 06 October 2008) From yeast to alkaloids.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09197<![CDATA[( BUPP09198 - 06 October 2008) beta-Endorphin and drug-induced reward and reinforcement.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09198<![CDATA[( BUPP09199 - 06 October 2008) Pain and medical treatment for pain in gynecology.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09199<![CDATA[( BUPP09200 - 06 October 2008) The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09200<![CDATA[( BUPP09201 - 06 October 2008) The direct comparison of health and ulcerated stomach tissue: A multiple probe microdialysis sampling approach.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09201<![CDATA[( BUPP09202 - 06 October 2008) Transdermal buprenorphine in clinical daily practice: Effectiveness and tolerability in patients suffering fom chronic musculoskeletal pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09202<![CDATA[( BUPP09203 - 07 October 2008) Commentary on Letter Entitled, "Buprenorphine Comes of Age".]]>http://coretext.org/bupp_detail.asp?recno=BUPP09203<![CDATA[( BUPP09204 - 07 October 2008) The Case for Chronic Disease Management for Addiction]]>http://coretext.org/bupp_detail.asp?recno=BUPP09204<![CDATA[( BUPP09205 - 13 October 2008) Assessment of lung inflammation in a mouse model of smoke inhalation and burn injury: Strain-specific differences.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09205<![CDATA[( BUPP09206 - 13 October 2008) Opioid-induced hyperalgesia may be more frequent than previously thought]]>http://coretext.org/bupp_detail.asp?recno=BUPP09206<![CDATA[( BUPP0207 - 13 October 2008) Pain treatment with high-dose, controlled-release oxycodone: An Italian perspective.]]>http://coretext.org/bupp_detail.asp?recno=BUPP0207160 mg/day) oxycodone controlled release (CR) for the treatment of cancer and non-cancer pain. Design: 227 patients with cancer or non-cancer pain were enrolled in an open-label, multi-center, Italian study in order to assess the adequacy of their existing pain management (using a numerical rating scale (NRS)) and the possible benefit high-dose oxycodone CR may offer patients experiencing uncontrolled pain. Results: Pain was poorly controlled at baseline, with only 18.1% of patients reporting adequate pain relief (NRS < 3.5). All other patients reported uncontrolled pain, with an average NRS of 7.81. At baseline assessment, 47.89% of patients had been in pain for up to 3 months, 32.82% for 3-6 months, and 19.19% for more than 6 months. After baseline assessment, patients were switched to oxycodone CR monotherapy. The starting dose was individualized to each patient and titrated up over a 3- to 4-day period until effective pain management was achieved. Treatment was continued for an average of 37.24 days during the study. Pain control (final mean NRS of 2.85) was attained with an average dose of oxycodone CR 221.84 mg/day. Standard adverse events (including constipations, nausea, and vomiting) were recorded in 39.64% of patients receiving high-dose oxycodone CR monotherapy. Side-effects tended to subside after the initial week of treatment and did not result in any participants leaving the study. Conclusion: Higb-dose oxycodone CR can achieve rapid and effective management of moderate to severe cancer and non-cancer pain with minimum side-effects. ]]><![CDATA[( BUPP09208 - 13 October 2008) Efficacy of pethidine and buprenorphine for prevention and treatment of postanesthetic shivering.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09208<![CDATA[( BUPP09209 - 13 October 2008) A new pathway]]>http://coretext.org/bupp_detail.asp?recno=BUPP09209<![CDATA[( BUPP09210 - 13 October 2008) Oxycodone/paracetamol: A guide to its use in the treatment of moderate to severe musculoskeletal pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09210<![CDATA[( BUPP09211 - 13 October 2008) Therapeutic strategies for persons addicted to opiates: The role of substitution treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09211<![CDATA[( BUPP09212 - 13 October 2008) A comprehensive review on the mode of action and the use of analgesics in different clinical pain states]]>http://coretext.org/bupp_detail.asp?recno=BUPP09212<![CDATA[( BUPP09207 - 13 October 2008) Pain treatment with high-dose, controlled-release oxycodone: An Italian perspective.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09207160 mg/day) oxycodone controlled release (CR) for the treatment of cancer and non-cancer pain. Design: 227 patients with cancer or non-cancer pain were enrolled in an open-label, multi-center, Italian study in order to assess the adequacy of their existing pain management (using a numerical rating scale (NRS)) and the possible benefit high-dose oxycodone CR may offer patients experiencing uncontrolled pain. Results: Pain was poorly controlled at baseline, with only 18.1% of patients reporting adequate pain relief (NRS < 3.5). All other patients reported uncontrolled pain, with an average NRS of 7.81. At baseline assessment, 47.89% of patients had been in pain for up to 3 months, 32.82% for 3-6 months, and 19.19% for more than 6 months. After baseline assessment, patients were switched to oxycodone CR monotherapy. The starting dose was individualized to each patient and titrated up over a 3- to 4-day period until effective pain management was achieved. Treatment was continued for an average of 37.24 days during the study. Pain control (final mean NRS of 2.85) was attained with an average dose of oxycodone CR 221.84 mg/day. Standard adverse events (including constipations, nausea, and vomiting) were recorded in 39.64% of patients receiving high-dose oxycodone CR monotherapy. Side-effects tended to subside after the initial week of treatment and did not result in any participants leaving the study. Conclusion: Higb-dose oxycodone CR can achieve rapid and effective management of moderate to severe cancer and non-cancer pain with minimum side-effects ]]><![CDATA[( BUPP09213 - 27 October 2008) Substitution treatment in Malaysia]]>http://coretext.org/bupp_detail.asp?recno=BUPP09213<![CDATA[( BUPP09214 - 27 October 2008) Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: The role of WHO (WPRO).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09214<![CDATA[( BUPP09215 - 27 October 2008) A short review of pharmacy practice in England.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09215<![CDATA[( BUPP09216 - 27 October 2008) Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09216<![CDATA[( BUPP09217 - 27 October 2008) Quantitative analysis of cocaine in human hair by HPLC with fluorescence detection.]]>http://coretext.org/bupp_detail.asp?recno=BUPP0921789%) and precision values (R.S.D. < 6.2%) were highly satisfactory. The method was successfully applied to hair samples collected from cocaine users. Thus, the method is suitable for the long-term monitoring of cocaine use by means of hair testing. ]]><![CDATA[( BUPP09218 - 27 October 2008) Prevention of Herpes Zoster infections in the elderly and management of post-herpetic neuralgia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09218<![CDATA[( BUPP09219 - 27 October 2008) Development and validation of a stability indicating HPLC method for the determination of buprenorphine in transdermal patch.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09219<![CDATA[( BUPP09220 - 27 October 2008) Imaging of opioid receptors in the central nervous system.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09220<![CDATA[( BUPP09221 - 27 October 2008) Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: Application intervals, metabolism and immunosuppression.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09221<![CDATA[( BUPP09222 - 27 October 2008) Topical application of morphine and buprenorphine gel has no effect in the sunburn model.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09222<![CDATA[( BUPP09223 - 27 October 2008) /sup 153/ Sm: Its use in multiple myeloma and report of a clinical experience.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09223<![CDATA[( BUPP09224 - 27 October 2008) Neuropathic pain - The case for opioid therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09224<![CDATA[( BUPP09225 - 27 October 2008) Pharmacotherapeutic guideline for pain management.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09225<![CDATA[( BUPP09226 - 27 October 2008) Illicit drug use and liver transplantation: Is there a problem and what is the solution?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09226<![CDATA[( BUPP09227 - 27 October 2008) A survey of cancer pain status in Shanghai]]>http://coretext.org/bupp_detail.asp?recno=BUPP09227<![CDATA[( BUPP09228 - 27 October 2008) The selection and use of essential medicines]]>http://coretext.org/bupp_detail.asp?recno=BUPP09228<![CDATA[( BUPP09229 - 27 October 2008) High dose transdermal buprenorphine for moderate to severe pain in Spanish pain centres - A retrospective multicenter safety and efficacy study.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09229<![CDATA[( BUPP09230 - 03 November 2008) Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09230<![CDATA[( BUPP09231 - 03 November 2008) Comparison of consumption of opioid analgesics and analgesics-antipyretics in Slovakia and in Finland.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09231<![CDATA[( BUPP09232 - 03 November 2008) Effect of selenium compound (selol) on the opioid activity in vincristine induced hyperalgesia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09232<![CDATA[( BUPP09233 - 03 November 2008) Interventional pain treatments for cancer pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09233<![CDATA[( BUPP09234 - 03 November 2008) Cancer pain and analgesia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09234<![CDATA[( BUPP09235 - 03 November 2008) Sublingual drug delivery.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09235<![CDATA[( BUPP09237 - 03 November 2008) Neuropsychological functioning of opiate-dependent patients: A nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment]]>http://coretext.org/bupp_detail.asp?recno=BUPP09237<![CDATA[( BUPP09238 - 03 November 2008) "Narcotics helped, I thought." Recurrent traumatization and recovery from drug dependence.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09238<![CDATA[( BUPP09239 - 03 November 2008) Office-based treatment in opioid dependence: A critical survey of prescription practices for opioid maintenance medications and concomitant benzodiazepines in Vienna, Austria.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09239<![CDATA[( BUPP09240 - 03 November 2008) Post-treatment outcomes of buprenorphine detoxification in community settings: A systematic review.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09240<![CDATA[( 09241 - 03 November 2008) Retention in substitution programmes with buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=09241<![CDATA[( BUPP09241 - 03 November 2008) Retention in substitution programmes with buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09241<![CDATA[( BUPP09242 - 03 November 2008) Methadone versus buprenorphine for inpatient detoxification treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09242<![CDATA[( BUPP09243 - 03 November 2008) Hair analysis for psychoactive substances in comparison to urine analysis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09243<![CDATA[( BUPP09244 - 03 November 2008) A national survey of postoperative pain management in France: Influence of type of surgical centres.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09244 90%) without any difference between centres. In all centres, POP evaluation tool were by decreasing frequency, numerical scale, nonspecific tool, visual analog scale and verbal scale. In all institutions, pain was rarely a criterion for recovery room discharge. Reported POP was mild at rest, moderate when moving and intense for maximal pain with no difference between centres. Incidence of side-effects was similar in all centres according to patient or chart, with mainly nausea and vomiting. Analgesics were frequently started during anaesthesia. Patient-controlled analgesia was used less frequently than subcutaneous morphine whose prescription frequently did not follow guidelines especially in small hospital. Non opioid analgesic included paracetamol, ketoprofen mainly in private structure and nefopam mainly in university hospital. Epidural or peripheral nerve blocks were underused similarly in all centres. Evaluation or treatment protocols were less frequent in university hospital. Conclusion: This national, prospective, patient-based, observational survey reveals similar achievements in different surgical centres but also some differences and persistent challenges for POP management. ]]><![CDATA[( BUPP09245 - 03 November 2008) Conscious and anesthetized non-human primate safety pharmacology models: Hemodynamic sensitivity comparison.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09245<![CDATA[( BUPP09246 - 10 November 2008) Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.]]>http://coretext.org/bupp_detail.asp?recno=BUPP092464. As free buprenorphine concentration and percentage free buprenorphine increased, head circumference decreased. Thrice-weekly urine tests for opiates, cocaine, and benzodiazepines and self-reported smoking data from the mother were compared with data from analysis of the meconium to estimate in utero exposure. Time of last drug use and frequency of use during the third trimester were important factors associated with drug-positive meconium specimens. The results suggest that buprenorphine and metabolite concentrations in the meconium may predict the onset and frequency of NAS. ]]><![CDATA[( BUPP09247 - 10 November 2008) Management of chronic pain in the elderly: Focus on transdermal buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09247<![CDATA[( BUPP09248 - 10 November 2008) Potent analgesic effect of tissue-engineered skin in a terminal patient with severe leg ulcer pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09248<![CDATA[( BUPP09249 - 10 November 2008) The Disease of Addiction: Origins, Treatment, and Recovery.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09249<![CDATA[( BUPP09250 - 10 November 2008) The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09250<![CDATA[( BUPP09251 - 10 November 2008) Life-threatening wound treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09251<![CDATA[( BUPP09252 - 10 November 2008) Effect of subcutaneous injection and oral voluntary ingestion of buprenorphine on post-operative serum corticosterone levels in male rats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09252<![CDATA[( BUPP09253 - 10 November 2008) Treatment of opioid dependence via home-based telepsychiatry.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09253<![CDATA[( BUPP09254 - 10 November 2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09254<![CDATA[( BUPP09255 - 10 November 2008) The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09255<![CDATA[( BUPP09256 - 10 November 2008) Extended vs Short-term Buprenorphine-Naloxone for Treatment of opioid-Addicted Youth - A Randomized Trial]]>http://coretext.org/bupp_detail.asp?recno=BUPP09256<![CDATA[( BUPP09257 - 17 November 2008) Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09257<![CDATA[( BUPP09258 - 17 November 2008) Magnesium ions and opioid agonist activity in streptozotocin-induced hyperalgesia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09258<![CDATA[( BUPP09259 - 17 November 2008) Propoxyphene: A drug with unfavorable risk-benefit characteristics.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09259<![CDATA[( BUPP09260 - 17 November 2008) Office-based opioid addiction treatment, and the rise in unintentional pediatric buprenorphine ingestions reported to a regional poison center - A new challenge for poison educators.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09260<![CDATA[( BUPP09261 - 17 November 2008) Changes in caller type for drug identification calls reported to a regional poison center over time.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09261<![CDATA[( BUPP09262 - 17 November 2008) Persistent toxicity after suboxone ingestion in a toddler.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09262<![CDATA[( BUPP09263 - 17 November 2008) A retrospective review of unintentional pediatric buprenorphine ingestions reported to a regional poison center.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09263<![CDATA[( BUPP09264 - 17 November 2008) Treatment of adolescent opioid dependence: no quick fix.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09264<![CDATA[( BUPP09265 - 17 November 2008) Analgesics and palliative care.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09265<![CDATA[( BUPP09266 - 17 November 2008) Perioperative Pain Management in Veterinary Patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09266<![CDATA[( BUPP09267 - 17 November 2008) Analgesia for the Critically Ill Dog or Cat: An Update.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09267<![CDATA[( BUPP09268 - 17 November 2008) Pain Management for the Pregnant, Lactating, and Neonatal to Pediatric Cat and Dog.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09268<![CDATA[( BUPP09269 - 17 November 2008) Managing Pain in Feline Patients]]>http://coretext.org/bupp_detail.asp?recno=BUPP09269<![CDATA[( BUPP09270 - 17 November 2008) Control of Cancer Pain in Veterinary Patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09270<![CDATA[( BUPP09271 - 17 November 2008) Epidural Analgesia and Anesthesia in Dogs and Cats.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09271<![CDATA[( BUPP09272 - 17 November 2008) Adjunctive Analgesic Therapy in Veterinary Medicine]]>http://coretext.org/bupp_detail.asp?recno=BUPP09272<![CDATA[( BUPP09273 - 17 November 2008) Pharmacological treatment of schizophrenia and co-occurring substance use disorders.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09273<![CDATA[( BUPP09274 - 17 November 2008) An interventional study to improve the quality of analgesia in the emergency department.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09274<![CDATA[( BUPP09275 - 17 November 2008) Guidelines of the German Society for Addiction Medicine (DGS e.V.), the German AIDS Society (DAIG) and the German association of physicians in private practice treating HIV-infected persons (DAGNAe) : HIV infection in intravenous drug addicts (IVDA).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09275<![CDATA[( BUPP09276 - 17 November 2008) Addiction and cognitive functions.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09276<![CDATA[( BUPP09277 - 17 November 2008) Step-by-step plan for pain management.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09277<![CDATA[( BUPP09278 - 17 November 2008) Organisation of acute pain therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09278<![CDATA[( BUPP09279 - 17 November 2008) New and evidence-based aspects of postoperative pain therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09279<![CDATA[( BUPP09280 - 17 November 2008) Treatment of opioid-dependent pregnant women: Clinical and research issues.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09280<![CDATA[( BUPP09281 - 24 November 2008) Ketamine-based total intravenous anesthesia versus isoflurane anesthesia in a swine model of hemorrhagic shock.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09281 0.1). The ISO group had a lower MAP at baseline (p = 0.02), at injury (p = 0.004), and study completion (p = 0.001). After resuscitation, MAP decreased in the ISO group but remained stable in the TIVA group. StO2 was significantly higher in the TIVA group immediately after injury (p = 0.004), but similar between groups throughout the remainder of the study. Animals who received TIVA trended toward higher levels of lactate and lower pH throughout the study, reaching significance at 30 minutes postinjury (p = 0.037 and 0.043). Inflammatory cytokine (IL-6, IL-8, and TNF-alpha) production did not differ between groups, however TNF-alpha mRNA production was significantly lower in the TIVA group (p = 0.04). CONCLUSION: Although a TIVA regimen produced less pronounced hypotension in a swine model of UHS than did ISO, end-organ perfusion with TIVA appeared to be equivalent or inferior to ISO. In circumstances of limited resources, such as those experienced by forward Army surgical teams, a ketamine-based TIVA regimen may be an option for use in UHS. ]]><![CDATA[( BUPP09282 - 24 November 2008) Opioid-induced immunosuppression.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09282<![CDATA[( BUPP09283 - 24 November 2008) Methadone and buprenorphine related ambulance attendances: A population-based indicator of adverse events.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09283<![CDATA[( BUPP09284 - 24 November 2008) Abuse-deterrent opioid formulations: Are they a pipe dream?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09284<![CDATA[( BUPP09285 - 24 November 2008) Steps of practical management.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09285<![CDATA[( BUPP09286 - 24 November 2008) Analgesia and renal failure.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09286<![CDATA[( BUPP09287 - 24 November 2008) Managing acute pain in patients with an opioid abuse or dependence disorder.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09287<![CDATA[( BUPP09288 - 24 November 2008) Occurrence of ethanol and other drugs in blood and urine specimens from female victims of alleged sexual assault.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09288<![CDATA[( BUPP09289 - 24 November 2008) Successful transition to buprenorphine in a patient with methadone induced torsades de pointes.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09289<![CDATA[( BUPP09290 - 24 November 2008) Ins and outs of neurologic therapy for chronic pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09290<![CDATA[( BUPP09291 - 24 November 2008) Detecting signs of opioid abuse and treating the addiction.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09291<![CDATA[( BUPP09292 - 01 December 2008) Immune-mediated neuropathies in myeloma patients treated with bortezomib.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09292<![CDATA[( BUPP09293 - 01 December 2008) Pain and the pharmacogenetics at the fuzzy border between pain physiopathology and pain treatment.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09293<![CDATA[( BUPP09294 - 01 December 2008) Showing-off muscles: Be aware of doping signs.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09294<![CDATA[( BUPP09295 - 01 December 2008) Buccoadhensive drug delivery systems - Extensive review on recent patents.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09295<![CDATA[( BUPP09296 - 01 December 2008) Drug addiction in China.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09296<![CDATA[( BUPP09297 - 01 December 2008) A French prospective observational study of the treatment of chronic hepatitis C in drug abusers.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09297<![CDATA[( BUPP09298 - 01 December 2008) Substance Abuse and Withdrawal in the Critical Care Setting.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09298<![CDATA[( BUPP09299 - 01 December 2008) Transdermal buprenorphine to treat pain in sickle cell crisis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09299<![CDATA[( BUPP09300 - 01 December 2008) Implementation of Drug Substitution Therapy in Georgia]]>http://coretext.org/bupp_detail.asp?recno=BUPP09300<![CDATA[( BUPP09301 - 01 December 2008) Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09301<![CDATA[( BUPP09302 - 01 December 2008) Electrocardiographic abnormalities in opiate addicts]]>http://coretext.org/bupp_detail.asp?recno=BUPP09302<![CDATA[( BUPP09303 - 01 December 2008) Opioids and Cardiogram Abnormalities: Providing treatment based on understanding the risks and benefits.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09303<![CDATA[( BUPP09304 - 01 December 2008) Letter to the Editor: The use of sublingual Buprenorphine-Naloxone for reversing heroin overdose: A high risk strategy that should not be recommended.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09304<![CDATA[( BUPP09305 - 01 December 2008) Letter to the Editor: The use of Buprenorphine to reverse opioid overdose deserves further evaluation.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09305<![CDATA[( BUPP09306 - 01 December 2008) When a New Drug Promotes the Integration of Treatment Modalities: Suboxone and Harm Reduction]]>http://coretext.org/bupp_detail.asp?recno=BUPP09306<![CDATA[( BUPP09307 - 01 December 2008) The Under-Treatment of Pain: A Global Problem. An Educational Approach]]>http://coretext.org/bupp_detail.asp?recno=BUPP09307<![CDATA[( BUPP09308 - 01 December 2008) Finnish Experience With Buprenorphine-Naloxone Combination (Suboxone): Survey Evaluations With Intravenous Drug Users]]>http://coretext.org/bupp_detail.asp?recno=BUPP09308<![CDATA[( BUPP09309 - 01 December 2008) Letter to the editor: Fifteen Years of Office Based Prescribing in Croatia. Attitudes, Obstacles and Outcomes.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09309<![CDATA[( BUPP09310 - 05 December 2008) Opiate agonist tretament for addiction (Correspondence letter)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09310<![CDATA[( BUPP09311 - 08 December 2008) Comparison of sevoflurane and isoflurane in dogs anaesthetised for clinical surgical or diagnostic procedures.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09311<![CDATA[( BUPP09312 - 08 December 2008) Sublingual bioavailability of buprenorphine in newborns with neonatal abstinence syndrome - a case study an physiological and developmental changes using SIMCYP.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09312<![CDATA[( BUPP09313 - 08 December 2008) Population pharmacokinetic investigation of ribavirin in pediatric subjects infected with hepatitis C virus]]>http://coretext.org/bupp_detail.asp?recno=BUPP09313<![CDATA[( BUPP09314 - 08 December 2008) Psychotherapeutic benefits of opioid agonist therapy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09314<![CDATA[( BUPP09315 - 08 December 2008) Electrocardiogram characteristics of methadone and buprenorphine maintained subjects.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09315<![CDATA[( BUPP09316 - 08 December 2008) Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence]]>http://coretext.org/bupp_detail.asp?recno=BUPP09316<![CDATA[( BUPP09317 - 08 December 2008) Addiction to Prescription Opioids: Characteristics of the Emerging Epidemic and Treatment With Buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09317<![CDATA[( BUPP09318 - 08 December 2008) Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions]]>http://coretext.org/bupp_detail.asp?recno=BUPP09318<![CDATA[( BUPP09319 - 08 December 2008) Sex Differences in Analgesic, Reinforcing, Discriminative, and Motoric Effects of Opioids.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09319<![CDATA[( BUPP09320 - 08 December 2008) Comparison between continuous propofol infusion & conventional balanced anaesthesia in neurosurgical patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09320<![CDATA[( BUPP09321 - 08 December 2008) Pain therapy - Dosing recommendations at beginning and end of treatment]]>http://coretext.org/bupp_detail.asp?recno=BUPP09321<![CDATA[( BUPP09322 - 16 December 2008) Guidelines: Control of pain in adults with cancer: Summary of SIGN guidelines.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09322<![CDATA[( BUPP09323 - 16 December 2008) Effects of cocaine in the human beings.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09323<![CDATA[( BUPP09324 - 16 December 2008) Fifteen years of office-based prescribing in Croatia. Attitudes, obstacles and outcomes.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09324<![CDATA[( BUPP09325 - 16 December 2008) The use of buprenorphine to reverse opioid overdose deserves further evaluation.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09325<![CDATA[( BUPP09326 - 16 December 2008) Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09326<![CDATA[( BUPP09327 - 16 December 2008) The use of sublingual buprenorphine-naloxone for reversing heroin overdose: A high-risk strategy that should not be recommended.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09327<![CDATA[( BUPP09328 - 16 December 2008) The use of depot naltrexone under legal coercion: The case for caution.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09328<![CDATA[( BUPP09329 - 16 December 2008) Unplanned admissions to two Sydney public hospitals after naltrexone implants.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09329<![CDATA[( BUPP09330 - 16 December 2008) Prevalence of diversion and injection of methadone and buprenorphine among clients opioid treatment at community pharmacies in New South Wales, Australia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09330<![CDATA[( BUPP09331 - 16 December 2008) Obstiless reports impact of opioid-induced side-effects.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09331<![CDATA[( BUPP09332 - 17 December 2008) Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: Preliminary results of an open randomized study .]]>http://coretext.org/bupp_detail.asp?recno=BUPP09332<![CDATA[( BUPP09333 - 22 December 2008) Cognitive Functioning During Methadone and Buprenorphine Treatment Results of a Randomized Clinical Trial.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09333<![CDATA[( BUPP09334 - 22 December 2008) Urine buprenorphine - A pilot study]]>http://coretext.org/bupp_detail.asp?recno=BUPP09334<![CDATA[( BUPP09335 - 22 December 2008) A simple gas chromatography-mass spectrometry procedure for the simultaneous determination of buprenorphine and norbuprenorphine in human urine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09335<![CDATA[( BUPP09336 - 22 December 2008) Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09336<![CDATA[( BUPP09337 - 22 December 2008) Outbreak of exogenous Cushing's syndrome due to unlicensed medications.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09337<![CDATA[( BUPP09338 - 22 December 2008) Transdermal drug delivery has ideal properties in the elderly.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09338<![CDATA[( BUPP09339 - 22 December 2008) Pain therapy in case of renal disease and chronic renal insufficiency.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09339<![CDATA[( BUPP09340 - 22 December 2008) Transdermal buprenorphine intoxication.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09340<![CDATA[( BUPP09341 - 22 December 2008) Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09341<![CDATA[( BUPP09342 - 22 December 2008) Prenatal buprenorphine exposure: Effects on biochemical markers of hypoxia and early neonatal outcome.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09342<![CDATA[( BUPP09343 - 05 January 2009) Analysis of a range of narcotic and psychotropic substances.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09343<![CDATA[( BUPP09344 - 05 January 2009) The prevalence of borderline personality among buprenorphine patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09344<![CDATA[( BUPP09345 - 05 January 2009) Treating opioid dependency and coexistent chronic nonmalignant pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09345<![CDATA[( BUPP09346 - 05 January 2009) New guidelines against unfair treatment of narcotic addicts necessary]]>http://coretext.org/bupp_detail.asp?recno=BUPP09346<![CDATA[( BUPP09347 - 05 January 2009) Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the veterans health administration.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09347<![CDATA[( BUPP09348 - 05 January 2009) Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09348<![CDATA[( BUPP09349 - 05 January 2009) Post marketing surveillance study with an analgesic (transdermal buprenorphine patch in patients with moderate to severe chronic pain).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09349<![CDATA[( BUPP09350 - 05 January 2009) Transdermal Buprenorphine in Children With Cancer-Related Pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09350<![CDATA[( BUPP09351 - 05 January 2009) Update in Addiction Medicine for the Primary Care Clinician.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09351<![CDATA[( BUPP09352 - 05 January 2009) Allergic contact dermatitis from transdermal buprenorphine.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09352<![CDATA[( BUPP09353 - 05 January 2009) Challenges in providing drug user treatment services in Russia: Providers' views.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09353<![CDATA[( BUPP09354 - 05 January 2009) Long-term recovery from heroin use among female ex-offenders: Marisol's story.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09354<![CDATA[( BUPP09355 - 05 January 2009) Substance Use & Misuse: Editorial.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09355<![CDATA[( BUPP09356 - 05 January 2009) Views and models about addiction: Differences between treatments for alcohol-dependent people and for illicit drug consumers in Italy.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09356<![CDATA[( BUPP09357 - 05 January 2009) Endogenous opiates and behavior: 2007.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09357<![CDATA[( BUPP09359 - 12 January 2009) Hospital morbidity associated with the natural history of heroin use.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09359<![CDATA[( BUPP09360 - 12 January 2009) Intrathecal drug delivery for management of cancer and noncancer pain.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09360<![CDATA[( BUPP09361 - 12 January 2009) Opiate agonist treatment for addiction - Authors' reply.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09361<![CDATA[( BUPP09362 - 12 January 2009) Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09362<![CDATA[( BUPP09363 - 12 January 2009) Oral or transdermal opioids for osteoarthritis of the knee or hip.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09363<![CDATA[( BUPP09364 - 12 January 2009) Maintenance treatments for opiate dependent adolescent.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09364<![CDATA[( BUPP09365 - 12 January 2009) Consumer satisfaction with opioid treatment services at community pharmacies in Australia.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09365<![CDATA[( BUPP09366 - 12 January 2009) Comparison of nonhydrolysis and hydrolysis methods for the determination of buprenorphine metabolites in urine by liquid chromatography-tandem mass spectrometry.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09366<![CDATA[( BUPP09380 - 26 January 2009) Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09380<![CDATA[( BUPP09381 - 26 January 2009) Opioid dependent patients' experiences of and attitudes towards having their injecting sites examined.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09381<![CDATA[( BUPP09382 - 26 January 2009) An enhanced method for the review of CD prescribing, based on ePACT data]]>http://coretext.org/bupp_detail.asp?recno=BUPP09382<![CDATA[( BUPP09383 - 26 January 2009) Interventions to reduce HIV transmission related to injecting drug use in prison.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09383<![CDATA[( BUPP09384 - 26 January 2009) Medications for Stimulant Abuse: Agonist-Based Strategies and Preclinical Evaluation of the Mixed-Action D(2) Partial Agonist Aripiprazole (Abilify(R)).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09384<![CDATA[( BUPP09385 - 26 January 2009) Local Inhibition of Rho Signaling by Cell-Permeable Recombinant Protein BA-210 Prevents Secondary Damage and Promotes Functional Recovery following Acute Spinal Cord Injury.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09385<![CDATA[( BUPP09386 - 26 January 2009) Neonatal outcome following buprenorphine maintenance for opiate dependency.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09386<![CDATA[( BUPP09387 - 26 January 2009) Pegylated interferon alfa-2a (peg-2a) plus ribavirin (rbv) for patients with chronic Hepatitis C virus (HCV) on opioid pharmacotherapy: virological outcomes, psychological impact and safety.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09387<![CDATA[( BUPP09388 - 26 January 2009) High rates of sustained virological response in HCV-infected injection drug users receiving directly observed therapy with peginterferon alfa-2a and once daily ribavirin.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09388<![CDATA[( BUPP09389 - 26 January 2009) Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09389<![CDATA[( BUPP09390 - 26 January 2009) Buprenorphine transdermal system in chronic pain due to osteoarthritis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09390<![CDATA[( BUPP09391 - 03 February 2009) Pharmacokinetics of buprenorphine after single-dose subcutaneous administration in red-eared sliders (Trachemys scripta elegans).]]>http://coretext.org/bupp_detail.asp?recno=BUPP09391<![CDATA[( BUPP09392 - 03 February 2009) DOTS in drug addicts with TB : Delhi experience.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09392<![CDATA[( BUPP09393 - 03 February 2009) Integration of viral hepatitis services into opioid treatment programs.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09393<![CDATA[( BUPP09394 - 03 February 2009) Adverse reactions to drug withdrawal.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09394<![CDATA[( BUPP09395 - 03 February 2009) Low-dose strong opioid (LDSO) - Treatment of pain in osteoarthritis.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09395<![CDATA[( BUPP09396 - 03 February 2009) Medications, drugs and alcohol in road traffic.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09396<![CDATA[( BUPP09397 - 03 February 2009) "Maintenance" treatment of addiction: To whose credit, and why it matters.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09397<![CDATA[( BUPP09398 - 09 February 2009) Treatment of opioid withdrawal]]>http://coretext.org/bupp_detail.asp?recno=BUPP09398<![CDATA[( BUPP09399 - 09 February 2009) General practitioner views on drug-assisted rehabilitation and the Norwegian substance abuse reform]]>http://coretext.org/bupp_detail.asp?recno=BUPP09399> have obtained ordinary patient rights according to the Patients Rights Act. General practitioners are supposed to follow up these patients, by prescribing opiates to those eligible for substitution therapy, and by participating in local <>. We wanted to investigate how general practitioners' perceive their involvement in substitution therapy, and to see whether this view had changed from 2000 to 2006. MATERIAL AND METHODS: Postal questionnaires were sent to 1606 doctors in 2000 and to 1400 of the same doctors in 2006. Of the 1318 (82 %) who responded in 2000, 227 were general practitioners and 78 were municipal medical officers; of the 966 (69 %) who responded in 2006, 227 were regular general practitioners. 208 of these had also responded in 2000. In 2006 we also asked the doctors about the recent substance abuse reform. RESULTS: 53 % of the general practitioners were in favour of substitution therapy with methadone or buprenorfine; 50 % said they might prescribe the drugs themselves and 77 % were positive towards participating in "responsibility groups". Two thirds felt that transferral of responsibility for patients with substance abuse problems to the specialist health care service, was a necessary and useful reform. The fraction of doctors with a positive attitude towards substitution therapy increased slightly from 2000 to 2006, but individual viewpoints varied largely. INTERPRETATION: Political and cultural rather than medical arguments seem to dominate doctors' views on these issues. ]]><![CDATA[( BUPP09400 - 09 February 2009) Tolerance to the antinociceptive effects of peripherally administered opioids. Expression of beta-arrestins]]>http://coretext.org/bupp_detail.asp?recno=BUPP09400<![CDATA[( BUPP09401 - 09 February 2009) Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine]]>http://coretext.org/bupp_detail.asp?recno=BUPP09401<![CDATA[( BUPP09402 - 09 February 2009) Methicillin-Susceptible Staphyloccocus aureus (MSSA) Bacteremias in Intravenous Buprenorphine Abusers: An Emerging Pathogen in Highly Regulated Singapore]]>http://coretext.org/bupp_detail.asp?recno=BUPP09402<![CDATA[( BUPP09403 - 09 February 2009) Novel medications to treat addictive disorders]]>http://coretext.org/bupp_detail.asp?recno=BUPP09403<![CDATA[( BUPP09404 - 09 February 2009) A French prospective observational study of the treatment of chronic hepatitis C in drug abusers: A commentary.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09404<![CDATA[( BUPP09405 - 09 February 2009) Potential use of dopamine partial agonists in cocaine addiction]]>http://coretext.org/bupp_detail.asp?recno=BUPP09405<![CDATA[( BUPP09424 - 16 February 2009) Buprenorphine tapering schedule and illicit opioid use]]>http://coretext.org/bupp_detail.asp?recno=BUPP09424<![CDATA[( BUPP09423 - 16 February 2009) Comparison of Side Effects between Buprenorphine and Meloxicam Used Postoperatively in Dutch Belted Rabbits (Oryctolagus cuniculus)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09423<![CDATA[( BUPP09422 - 16 February 2009) Model for Clinical Evaluation of Perioperative Analgesia in the Rabbit]]>http://coretext.org/bupp_detail.asp?recno=BUPP09422<![CDATA[( BUPP09421 - 16 February 2009) Castration Eliminates Conspecific Aggression in Group-housed Male Surveillance Mice]]>http://coretext.org/bupp_detail.asp?recno=BUPP09421<![CDATA[( BUPP09419 - 16 February 2009) Evaluation of Perioperative Analgesia on Behavioral Tests in the Chronic Constriction Injury Neuropathic Pain Model]]>http://coretext.org/bupp_detail.asp?recno=BUPP09419<![CDATA[( BUPP09418 - 16 February 2009) In Vitro Skin Permeation of Buprenorphine Transdermal Patch.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09418 linolenic acid > menthol > oleic acid > N-methyl-2-pyrrolidone (NMP) > laurocapram > glabridin. Finally, a matrix-type transdermal delivery system for buprenorphine was formulated using acrylic adhesive, PG, and lauric acid. The J(ss) parameter was 2.68 +/- 0.20 mu g/cm(2)/h and buprenorphine permeated across the nude mouse skin was 31.68%. ]]><![CDATA[( BUPP09417 - 16 February 2009) The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?]]>http://coretext.org/bupp_detail.asp?recno=BUPP09417<![CDATA[( BUPP09415 - 16 February 2009) Mucositis in the treatment of haematological malignancies.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09415<![CDATA[( BUPP09414 - 16 February 2009) The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09414<![CDATA[( BUPP09413 - 16 February 2009) Introduction to a Symposium on Recent Advances in the Development of Medications for Drug Abuse Treatment in Honor of Jack H. Mendelson, MD.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09413<![CDATA[( BUPP09411 - 16 February 2009) Treating drug abuse and addiction in the criminal justice system: Improving public health and safety.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09411<![CDATA[( BUPP09410 - 16 February 2009) Delayed-onset neutropenia associated with divalproex sodium; Acute psychosis induced by clarithromycin; Acute phase reaction with ibandronate; Duloxetine-associated tachycardia; Hepatotoxicity with valerian; Serotonin syndrome with a single dose of buprenorphine /naloxone.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09410<![CDATA[( BUPP09409 - 16 February 2009) Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies: Research report.]]>http://coretext.org/bupp_detail.asp?recno=BUPP0940930% of pain relief at day 42 visit. Five patients needed to increase the dosage to 52.5 mug/h. Eight patients did not meet the primary outcome, but none allowed increasing the dosage to 70 mug/h, and four patients withdrew consent to continue the study before day 42 visit because of a 'fear to become addicted,' although 40% had obtained VAS reduction. In our study, which needs to be confirmed by a controlled trial, buprenorphine TDS induced clinically meaningful pain relief in about 40% of patients with chronic painful neuropathy, suggesting its use as a third-line treatment. ]]><![CDATA[( BUPP09408 - 16 February 2009) Inhibition of inducible nitric oxide synthase reduces an acute peripheral motor neuropathy produced by dermal burn injury in mice: Research report.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09408<![CDATA[( BUPP09407 - 16 February 2009) Substance-related problems and treatment among men who have sex with men in comparison to other men in Chicago.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09407<![CDATA[( BUPP09420 - 16 February 2009) Effect of Buprenorphine Analgesia on Growth in Neonatal Mice]]>http://coretext.org/bupp_detail.asp?recno=BUPP09420<![CDATA[( BUPP09416 - 16 February 2009) (<< Puffy hands >> syndrome)]]>http://coretext.org/bupp_detail.asp?recno=BUPP09416<![CDATA[( BUPP09412 - 16 February 2009) Reinforcing Effects of Stimulants in Humans: Sensitivity of Progressive-Ratio Schedules.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09412<![CDATA[( BUPP09406 - 16 February 2009) Home buprenorphine/naloxone induction in primary care]]>http://coretext.org/bupp_detail.asp?recno=BUPP09406<![CDATA[( BUPP09367 - 15 January 2009) Cost analysis of clinic and office-basaed treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09367<![CDATA[( BUPP09368 - 15 January 2009) Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09368<![CDATA[( BUPP09369 - 16 January 2009) Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial.]]>http://coretext.org/bupp_detail.asp?recno=BUPP09369